Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 1 October 2007, Vol. 110, No. 7, pp. 2268-2275.
Prepublished online as a Blood First Edition Paper on June 27, 2007; DOI 10.1182/blood-2007-05-038950.

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
blood-2007-05-038950v1
110/7/2268    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rowe, J. M.
Right arrow Articles by Goldstone, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rowe, J. M.
Right arrow Articles by Goldstone, A. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted May 4, 2007
Accepted June 19, 2007

How I treat acute lymphocytic leukemia in adults

Jacob M. Rowe* and Anthony H. Goldstone

Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center & Technion, Israel Institute of Technology, Haifa, Israel
Director of Services, North London Cancer Network, UCL Hospitals, London, United Kingdom

* Corresponding author; email: rowe{at}jimmy.harvard.edu.

The treatment of newly diagnosed ALL in adults remains unsatisfactory. Not withstanding the outstanding progress in curing childhood ALL, only about one third of adults younger than 60 years can be cured, and the overall published survival curves have not changed significantly over the past 15 years. Recent therapeutic advances in allogeneic transplantation through the conduct of large collaborative studies; better understanding of the relevance of cytogenetics; improved molecular techniques for the detection of minimal residual disease, as well as clinical research into novel biologic and targeted therapies have all combined to offer potentially a better hope for an improved outcome in this disease. The current approach to the management in 2007 of this disease is presented by way of a discussion of illustrative cases. In this uncommon and difficult disease, well structured intergroup studies will remain vital for future progress.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Anticancer ResHome page
J. STYCZYNSKI, L. GIL, K. DERWICH, J. WACHOWIAK, W. BALWIERZ, W. BADOWSKA, M. KRAWCZUK-RYBAK, M. MATYSIAK, M. WIECZOREK, A. BALCERSKA, et al.
Comparison of Clofarabine Activity in Childhood and Adult Acute Leukemia: Individual Tumor Response Study
Anticancer Res, May 1, 2009; 29(5): 1643 - 1650.
[Abstract] [Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020